Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody

Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care

The HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.

Reported Earlier: 'BioNTech to shutter three sites in Germany as no buyers emerge' - Reuters

https://www.reuters.com/business/healthcare-pharmaceuticals/biontech-shutter-sites-germany-singapore-no-buyers-emerge-2026-09-28/

Why Is BioNTech Stock Gaining Monday?

BioNTech (BNTX) Phase 3 data reveals gotistobart almost doubles survival in advanced lung cancer over standard docetaxel.

Invivyd shares are trading lower after the company announced topline data from the LIBERTY Phase 3, randomized, double-blind, active-controlled study evaluating the safety and tolerability of VYD2311.

8-K filing — Invivyd, Inc. (IVVD)

Filed: 2026-09-29 AccNo: 0001193125-26-406007 Size: 12 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Invivyd Announces Clinically Meaningful And Statistically Significant Topline Data From Its LIBERTY Phase 3 Study Evaluating Safety And Tolerability Of VYD2311, COVID-19 vaccine COMIRNATY, And VYD2311 Co-Administered With mRNA-Based COVID-19 Vaccine

VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and tolerability that is clinically and statistically superior to the safety and